Lyra Therapeutics Investor Relations Material
Latest events
Study Result
Lyra Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Lyra Therapeutics Inc
Access all reports
Lyra Therapeutics Inc. is a clinical-stage biotechnology firm dedicated to developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). CRS is an inflammatory disease of the paranasal sinuses that results in prolonged periods of nasal congestion, facial pain, and nasal discharge. Leveraging expertise in materials science, drug development, and formulation, Lyra has introduced proprietary technology aimed at delivering medications directly, precisely, and consistently to the affected tissue for extended durations with a single administration. The company's leading product candidates include LYR-210 and LYR-220, both bioresorbable nasal implants designed for in-office procedures, intended to provide up to six months of continuous drug therapy to the sinonasal passages for CRS treatment. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
LYRA
Country
🇺🇸 United States